title: Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.
abstract: Mature T cell lymphoma has been noted for poor prognosis when compared with B cell lymphoma, even in the pre-rituximab era. To confirm this difference, a retrospective cohort study was conducted. One hundred-and nineteen patients with mature T cell lymphoma and 568 patients with diffuse large B cell lymphoma (DLBCL) who did not receive rituximab as first induction were studied. Overall survival (OS) was worse for patients with international prognostic index (IPI) scores indicating low-risk mature T cell lymphoma than for those with DLBCL (3-year OS 87 % vs. 58 %, P = 0.001), but not in other risk groups. Prognosis of mature T cell lymphoma was significantly poorer in the IPI low-risk group, as compared with DLBCL.
authors.affiliation: Clinical Hematology Group of National Hospital Organization, Nagoya, Japan.
authors.forename: Rika
authors.initials: R
authors.lastname: Kihara
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Watanabe
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yano
authors.forename: Naokuni
authors.initials: N
authors.lastname: Uike
authors.forename: Seiichi
authors.initials: S
authors.lastname: Okamura
authors.forename: Fumio
authors.initials: F
authors.lastname: Kawano
authors.forename: Shuichi
authors.initials: S
authors.lastname: Hanada
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Sunami
authors.forename: Nobumasa
authors.initials: N
authors.lastname: Inoue
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Yoshida
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimomura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kitano
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kojima
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000401:mortality* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult